Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Leanness Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2

NCT03743064
View directory record Official record
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
anamorelin HCl, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Tucson, Arizona • Anaheim, California • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

Creatine in Treating Patients With Cancer-Associated Weight Loss

NCT00081250
View directory record Official record
Conditions
Anorexia, Cachexia, Unspecified Adult Solid Tumor, Protocol Specific, Weight Changes
Interventions
creatine monohydrate, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
220
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 139 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Not applicable Interventional

Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy

NCT01941810
View directory record Official record
Conditions
Anorexia, Cachexia, Malignant Neoplasm, Oral Complications of Chemotherapy
Interventions
bovine lactoferrin supplement, questionnaire administration, quality-of-life assessment, laboratory biomarker analysis
Dietary Supplement · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 23, 2026, 5:44 PM EDT
Recruiting Phase 1 Interventional

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

NCT05865535
View directory record Official record
Conditions
Cachexia
Interventions
AV-380
Biological
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Beverly Hills, California • Lakewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women

NCT00072917
View directory record Official record
Conditions
Obesity, Thinness, Weight Gain
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2010 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

NCT00002127
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Greenbrae, California • Redwood City, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 5:44 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Not applicable Interventional

Food As Medicine for Heart Failure

NCT04847973
View directory record Official record
Conditions
Heart Failure, Malnutrition
Interventions
Medically-Tailored Meals (MTMs), Protein supplementation shakes
Other · Dietary Supplement
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

NCT02045940
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 23, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

NCT01015274
View directory record Official record
Conditions
Cachexia
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 75 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 23, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Puberty and Weight on Sugar Metabolism in Children

NCT01718080
View directory record Official record
Conditions
Overweight, Leanness, Adolescent
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy

NCT02330926
View directory record Official record
Conditions
Cachexia, Neoplasms
Interventions
standard care, nutritional supplements and advice, home-based self-assisted exercise program, Ibuprofen
Other · Dietary Supplement · Behavioral + 1 more
Lead sponsor
Norwegian University of Science and Technology
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 23, 2026, 5:44 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

NCT00637728
View directory record Official record
Conditions
Anorexia, Cachexia, Weight Loss
Interventions
Megestrol acetate concentrated suspension 110 mg/mL, Placebo
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Miami, Florida • Cumberland, Maryland • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 23, 2026, 5:44 PM EDT
Recruiting Phase 2Phase 3 Interventional

Visugromab in Cachexia International Trial

NCT07112196
View directory record Official record
Conditions
Cancer-associated Cachexia
Interventions
Visugromab (CTL-002), Placebo
Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Norwich, Connecticut • Clermont, Florida • Orange City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Terminated Not applicable Interventional Results available

Multimodal Treatment Strategy for Cancer Cachexia

NCT00625742
View directory record Official record
Conditions
Advanced Cancer, Cachexia
Interventions
Graded Resistance Training, Aerobic Exercise, Melatonin, Juven, Atenolol, Ibuprofen
Behavioral · Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

NCT00467844
View directory record Official record
Conditions
Cachexia
Interventions
GTx-024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
Not listed
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
50
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 23, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Anamorelin Study for Advanced Pancreatic Cancer

NCT04844970
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Anamorelin Hydrochloride, Placebo
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1

NCT03743051
View directory record Official record
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
Anamorelin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT07083557
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions
Endothelial cell collection
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept

NCT00034060
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

NCT01433263
View directory record Official record
Conditions
Cachexia
Interventions
BYM338 active drug, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

NCT01696604
View directory record Official record
Conditions
Cachexia
Interventions
GSK2849466, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

NCT04299048
View directory record Official record
Conditions
Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
PF-06946860
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Beverly Hills, California • Grand Junction, Colorado • Wheat Ridge, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 23, 2026, 5:44 PM EDT